Compare AbbVie Inc (ABBV) vs Oklo Inc (OKLO) Price & Performance

AbbVie IncTrade

Oklo IncTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs Oklo Inc — how do they compare? AbbVie Inc trades at $249.78 (market cap $441.94B), while Oklo Inc trades at $47.39 (market cap $8.74B). The key difference: AbbVie Inc is far larger — about 50.6× Oklo Inc's market cap, and AbbVie Inc pays a 2.77% dividend while Oklo Inc pays none. Which is the better fit depends on your goals.

	ABBV	OKLO
Market Cap	$441.94B	$8.74B
Sector	Health	Technology
52-Week High	$263.58	$174.14
52-Week Low	$197.38	$36.84
Enterprise Value	$506.19B	$6.28B
Dividend Yield	2.77%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.

Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.

Oklo Inc

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ABBV

Fidelity Dividend ETF's payout is safe but not ideal for steady income due to variable quarterly dividends.24/7 Wall Street · 23 hours agoNeutral Two Dividend Aristocrats outperformed the market while two lagged; three new picks show promising dividend growth.24/7 Wall Street · 2 days agoNeutral Healthcare sector leads S&P 500 gains over 3 months with key pharma stocks showing strong innovation and income potential.24/7 Wall Street · 2 days agoBullish View details →

OKLO

NuScale Power shares fall 32% YTD amid revenue drop and dilution, awaiting key contracts to rebound.24/7 Wall Street · 21 hours agoBearish Oklo posts first revenue with reactor milestone; AST SpaceMobile reports higher revenue but heavy launch loss.24/7 Wall Street · 1 day agoNeutral Oklo posts $1.2M Q2 revenue with 14% stock rise, but core tech validation and cost clarity remain uncertain.Seeking Alpha · 4 days agoNeutral View details →

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

About Oklo Inc

Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.